Data from Drugs of Today - Curated by EPG Health - Date available 01 November 2017
Availability
Pay for access, or by subscription
Article type
Review
Original date published
1 November 2017
Original format
Print publication
Tivozanib is a tyrosine kinase inhibitor that targets all vascular endothelial growth factor receptors (VEGFRs), causing inhibition of angiogenesis. It has recently been approved by the European Medicines Agency (EMA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive, following disease progression after one prior treatment with cytokine therapy for advanced RCC. This review will focus on mechanisms of action, early drug development and results of published and ongoing clinical trials of tivozanib.
Data sources
Read abstract on library site Access full article
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Prostate Cancer
How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?
+ 5 more
Chronic Lymphocytic Leukaemia (CLL)
Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more
+ 1 more
Breakthrough Cancer Pain Learning Zone
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
+ 2 more
Communicating Metastatic Breast Cancer Learning Zone
This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Related Content
Tivozanib: a new treatment option for renal cell carcinoma.
Tivozanib is a tyrosine kinase inhibitor that targets all vascular endothelial growth factor receptors (VEGFRs), causing inhibition of angiogenesis. It has recently been approved by the European Medicines Agency (EMA)...
Added 29 days ago
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.
Added 6 months ago
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Background: Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib...
Added 6 months ago
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
Introduction: In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited.
Added 1 year ago
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
Clear cell renal cell carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL loss drives tumor angiogenesis and accounts for the clinical activity ...
Added 1 year ago
FDA approves Mvasi (bevacizumab-awwb) biosimilar for non-small cell lung cancer, for metastatic colorectal cancer, glioblastoma, metastatic renal cell carcinoma and carcinoma of the cervix.- Amgen and Allergan.
Amgen and Allergan announced that the FDA has approved Mvasi (bevacizumab-awwb) for all eligible indications of the reference product, Avastin...
Added 7 months ago
Phase III CheckMate -214 study of Opdivo plus Yervoy (nivolumab + ipilimumab) in untreated advanced or metastatic renal cell carcinoma meets endpoint and advisory committee recommends halting study.- BMS.
Bristol-Myers Squibb announced that a Phase III CheckMate -214 study evaluating Opdivo plus Yervoy (nivolumab + ipilimumab) in patients with...
Added 7 months ago
Positive results from CheckMate -214 trial for Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib as a treatment for renal cell carcinoma. - BMS
Bristol-Myers Squibb Company announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab)...
Added 8 months ago
Analysis confirms PFS efficacy of endpoint results of Phase II CABOSUN trial of cabozantinib versus sunitinib for renal cell carcinoma and sDNA application for first line treatment.- Exelixis Inc.
Exelixis, Inc. announced that the analysis of the review by a blinded independent radiology review committee (IRC) has confirmed the...
Added 10 months ago
UK NICE gives draft guidance recommending use of Afinitor (everolimus) in advanced renal cell carcinoma- Novartis
The UK's National Institute for Health and Care Excellence has published new draft guidelines recommending Afinitor (everolimus), from Novartis, as...
Added 1 year ago
An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
This is an extension treatment protocol to allow access to tivozanib or sorafenib for subjects enrolled on AV-951-09-301(parent protocol). Subjects who failed sorafenib on the parent protocol will be offered tivozanib.
Added 29 days ago
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer (S-TRAC)
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
Added 6 months ago
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Added 4 years ago
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC.
Added 9 years ago
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]
This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC)...
Added 4 months ago
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively, thus representing the 7th most common cancer in men and the 10th most common cancer in women.
Added 3 years ago
Guidelines on Renal Cell Carcinoma
The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists with evidence-based information and recommendations for the management of renal cell cancer.
Added 2 years ago
Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS)
This overview represents the updated European Association of Urology (EAU) Guidelines for Non-muscle-invasive Bladder Cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented is limited to urothelial carcinoma...
Added 2 years ago
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.